N-[3-cyano-4-(4-methoxyphenyl)-5-methyl-2-thiophenyl]-2-methyl-3-pyrazolecarboxamide profile

ID Source	ID
PubMed CID	994824
CHEMBL ID	1483321
CHEBI ID	109210

Synonym
n-[3-cyano-4-(4-methoxyphenyl)-5-methylthiophen-2-yl]-2-methylpyrazole-3-carboxamide
OPREA1_756926
smr000227885
n-[3-cyano-4-(4-methoxyphenyl)-5-methyl-2-thienyl]-1-methyl-1h-pyrazole-5-carboxamide
MLS000704062 ,
n-[3-cyano-4-(4-methoxyphenyl)-5-methylthiophen-2-yl]-1-methyl-1h-pyrazole-5-carboxamide
STK429685
CHEBI:109210
BRD-K28513206-001-03-1
AKOS003307068
HMS2527J21
CHEMBL1483321
n-[3-cyano-4-(4-methoxyphenyl)-5-methyl-thiophen-2-yl]-2-methyl-pyrazole-3-carboxamide
bdbm74896
cid_994824
n-[3-cyano-4-(4-methoxyphenyl)-5-methyl-2-thiophenyl]-2-methyl-3-pyrazolecarboxamide
n-[3-cyano-4-(4-methoxyphenyl)-5-methyl-2-thienyl]-2-methyl-pyrazole-3-carboxamide
Q27188284

Class	Description
methoxybenzenes	Any aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	19.9526	0.1778	14.3909	39.8107	AID2147
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	7.0795	5.6234	17.2929	31.6228	AID485281
chaperonin-containing TCP-1 beta subunit homolog	Homo sapiens (human)	Potency	22.3872	3.9811	27.7649	39.8107	AID504842
TDP1 protein	Homo sapiens (human)	Potency	16.3601	0.0008	11.3822	44.6684	AID686978
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	4.4668	0.2818	9.7212	35.4813	AID2326
67.9K protein	Vaccinia virus	Potency	28.1838	0.0001	8.4406	100.0000	AID720579
IDH1	Homo sapiens (human)	Potency	12.9953	0.0052	10.8652	35.4813	AID686970
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	31.6228	0.0018	15.6638	39.8107	AID894
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	6.5131	0.0041	9.9848	25.9290	AID504444
huntingtin isoform 2	Homo sapiens (human)	Potency	35.4813	0.0006	18.4198	1,122.0200	AID1688
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	35.4813	0.0079	8.2332	1,122.0200	AID2546
geminin	Homo sapiens (human)	Potency	18.3564	0.0046	11.3741	33.4983	AID624297
Vpr	Human immunodeficiency virus 1	Potency	63.0957	1.5849	19.6264	63.0957	AID651644
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	10.0000	0.1259	12.2344	35.4813	AID1458
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	7.0795	0.0041	9.9625	28.1838	AID2675
lamin isoform A-delta10	Homo sapiens (human)	Potency	6.3096	0.8913	12.0676	28.1838	AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
karyopherin alpha 2 (RAG cohort 1, importin alpha 1), isoform CRA_b	Homo sapiens (human)	EC50 (µMol)	500.0000	0.9181	41.9368	121.5000	AID435026
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
unnamed protein product	Saccharomyces cerevisiae (brewer's yeast)	AC50	500.0000	0.0008	0.0008	0.0008	AID463208
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504787	Counterscreen for agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3): TR-FRET-based biochemical high throughput assay to identify agonists of the interaction between peroxisome proliferator-activated receptor gamma (PPARg) and nuclear rec	2006	Assay and drug development technologies, Jun, Volume: 4, Issue:3	Development of the high throughput screening assay for identification of agonists of an orphan nuclear receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	3 (50.00)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoic acid [no description available]	2.03	1	biotins
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	2.03	1	1-benzofurans; aromatic ketone	uricosuric drug
9,10-phenanthrenequinone 9,10-phenanthrenequinone: structure	2.03	1	phenanthrenes
benzo(b)fluoranthene benzo[b]fluoranthene : An ortho- and peri-fused polycyclic arene that consists of a benzene ring fused with a acephenanthrylene ring.	2.03	1	ortho- and peri-fused polycyclic arene	mutagen
malononitrile dimer Malononitrile dimer: has antithyroid activity; inhibits conversion of monoiodotyrosine to diiodotyrosine	2.03	1
toxoflavin toxoflavin: azapteridine antibiotic; structure. toxoflavin : A pyrimidotriazine that is 1,6-dimethyl-1,5,6,7-tetrahydropyrimido[5,4-e][1,2,4]triazine with oxo groups at positions 5 and 7.	2.03	1	carbonyl compound; pyrimidotriazine	antibacterial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; toxin; virulence factor; Wnt signalling inhibitor
methyl fluorone black methyl fluorone black: structure	2.03	1
6-hydroxydopa 6-hydroxydopa: RN given refers to cpd without isomeric designation	2.03	1	non-proteinogenic alpha-amino acid
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	2.03	1	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
desthiobiotin desthiobiotin: RN given refers to cpd without isomeric designation; structure. (4R,5S)-dethiobiotin : The (4R,5S)-isomer of dethiobiotin.	2.03	1	dethiobiotin
1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione [no description available]	2.03	1	pyrimidotriazine
5-bromo-3-ethyl-1H-indole-2-carboxylic acid [no description available]	2.03	1	indolyl carboxylic acid
2-(4-benzofuro[3,2-d]pyrimidinylthio)-1-thiophen-2-ylethanone [no description available]	2.03	1	benzofurans
3,5,5-trimethyl-2-sulfanylidene-1,6-dihydrobenzo[h]quinazolin-4-one [no description available]	2.03	1	quinazolines
2-amino-4-(4-chlorophenyl)-6-methyl-3-pyridinecarbonitrile [no description available]	2.03	1	phenylpyridine
1,6-dimethyl-3-(2-pyridinyl)pyrimido[5,4-e][1,2,4]triazine-5,7-dione [no description available]	2.03	1	pyrimidotriazine
1-(4-methyl-1-piperidinyl)-2-[(3-methyl-2-quinoxalinyl)thio]ethanone [no description available]	2.03	1	quinoxaline derivative
2-(4-fluorophenyl)-3-(2-furanylmethyl)-10-methylpyrimido[4,5-b]quinoline-4,5-dione [no description available]	2.03	1	quinolines
6-(4-bromophenyl)-3-methyl-1-[2-(2H-tetrazol-5-yl)ethyl]-4-(trifluoromethyl)pyrazolo[3,4-b]pyridine [no description available]	2.03	1	phenylpyridine
3-phenyl-2-sulfanylidene-1H-benzofuro[3,2-d]pyrimidin-4-one [no description available]	2.03	1	benzofurans
2-[(4-methylphenyl)sulfonylamino]acetic acid [2-(5-bromo-2-thiophenyl)-2-oxoethyl] ester [no description available]	2.03	1	alpha-amino acid ester
2-[(6-chloro-1H-benzimidazol-2-yl)thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide [no description available]	2.03	1	benzimidazoles
2-(4-benzofuro[3,2-d]pyrimidinylthio)-N-(3-methylphenyl)acetamide [no description available]	2.03	1	benzofurans
2-amino-7,7-dimethyl-4-(4-methylphenyl)-5-oxo-6,8-dihydro-4H-1-benzopyran-3-carbothioamide [no description available]	2.03	1	toluenes
1-(3-methyl-1-piperidinyl)-2-(2-quinoxalinylthio)ethanone [no description available]	2.03	1	quinoxaline derivative
2-(5-bromo-2-thiophenyl)-N-(4-methyl-1-piperazinyl)-4-quinolinecarboxamide [no description available]	2.03	1	quinolines
3-(4-chloro-1,5-dimethyl-3-pyrazolyl)-4-(4-fluorophenyl)-1H-1,2,4-triazole-5-thione [no description available]	2.03	1	triazoles
2-(2-quinoxalinylthio)propanoic acid [no description available]	2.03	1	quinoxaline derivative
ellagic acid [no description available]	2.03	1	catechols; cyclic ketone; lactone; organic heterotetracyclic compound; polyphenol	antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor; EC 2.4.1.1 (glycogen phosphorylase) inhibitor; EC 2.5.1.18 (glutathione transferase) inhibitor; EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor; EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor; EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; food additive; fungal metabolite; geroprotector; plant metabolite; skin lightening agent
3-bromo-7-hydroxy-4,8-dimethyl-1-benzopyran-2-one [no description available]	2.03	1	hydroxycoumarin
3-(3-methylphenyl)-2-sulfanylidene-1H-benzofuro[3,2-d]pyrimidin-4-one [no description available]	2.03	1	benzofurans
6-(4-bromophenyl)-2-methyl-3-pyridinecarboxylic acid [no description available]	2.03	1	phenylpyridine
lissamine rhodamine b lissamine rhodamine : An organic sodium salt having 4-[3,6-bis(diethylamino)xanthenium-9-yl]benzene-1,3-disulfonate as the counterion.	2.03	1	organic sodium salt	fluorescent probe; fluorochrome; histological dye
methacycline monohydrochloride [no description available]	2.03	1

Condition	Indicated	Relationship Strength	Studies	Trials
Innate Inflammatory Response [description not available]	0	2.05	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.05	1	0

N-[3-cyano-4-(4-methoxyphenyl)-5-methyl-2-thiophenyl]-2-methyl-3-pyrazolecarboxamide

Cross-References

Synonyms (18)

Drug Classes (1)

Protein Targets (19)

Potency Measurements

Activation Measurements

Other Measurements

Bioassays (14)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.41

Study Types

N-[3-cyano-4-(4-methoxyphenyl)-5-methyl-2-thiophenyl]-2-methyl-3-pyrazolecarboxamide

Cross-References

Synonyms (18)

Drug Classes (1)

Protein Targets (19)

Potency Measurements

Activation Measurements

Other Measurements

Bioassays (14)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.41

Study Types

Related Drugs (34)

Related Conditions (2)